跳至主要内容
临床试验/NCT05793008
NCT05793008招募中不适用

Characterization of priMary And sEcondary STress Related takOtsubo: the MAESTRO Pilot Study

Fondazione Policlinico Universitario Agostino Gemelli IRCCS2 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2023年3月30日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
入组人数
60
试验地点
2
主要终点
Association between brain activation and clinical profile and outcome in Takotsubo Syndrome

研究概览

简要总结

Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury often preceded by a physical or emotional trigger. Although TTS was generally considered a benign disease for its reversible nature, it is now clear that hemodynamic and electrical instability during the acute phase exposes patients to frequent serious adverse in-hospital complications. However, the pathophysiology of TTS is far from being completely understood. Consistent evidence demonstrated that the environmental events experienced by most of these patients and perceived as stressful (both physical or emotional) induce a brain activation and a stress-related response, with increasing bioavailability of local and circulating stress mediators, such as catecholamine and cortisol, which showed to play a major role in the etiology of to the "neurogenic stunning myocardium" responsible for this clinical condition.

Primary and secondary TTS showed an important clinical heterogeneity identifying two different subtypes of patients with different outcomes and risk profiles. the invastigators hypothesize that a different activation of the brain structures involved in acute stress response, as well as a different exposure to chronic stress, may subtend the different clinical and risk profiles observed in primary vs. secondary TTS patients. Moreover, the invastigators hypothesize that distinct signatures of circulating biomarkers may be associated with these two categories of TTS patients. Therefore, identifying these specific signatures may help in the diagnosis of these patients and pave the way for the identification of specific pathophysiologic pathways and the development of future therapies.

详细描述

Background and rationale Takotsubo syndrome (TTS) is an acute and reversible form of myocardial injury often preceded by a physical or emotional trigger. Although TTS was generally considered a benign disease for its reversible nature, it is now clear that hemodynamic and electrical instability during the acute phase exposes patients to frequent serious adverse in-hospital complications. However, the pathophysiology of TTS is far from being completely understood. Consistent evidence demonstrated that the environmental events experienced by most of these patients and perceived as stressful (both physical or emotional) induce a brain activation and a stress-related response, with increasing bioavailability of local and circulating stress mediators, such as catecholamine and cortisol, which showed to play a major role in the etiology of to the "neurogenic stunning myocardium" responsible for this clinical condition. Recent studies strengthened the hypothesis of an outstanding link between the brain stress response system and heart in TTS patients using neuroimaging approach. The fundamental anatomic structures involved in the stress response are the neocortex, limbic system, reticular formation, brainstem, and spinal cord along with the hypothalamic-pituitary-adrenal axis which finally leads to cortisol secretion. In this regard, substantial structural differences in the neocortex and the limbic network (insula, amygdala, cingulate cortex, and hippocampus), have been shown among TTS patients compared to healthy controls using brain functional magnetic resonance imaging (fMRI), along with a hypoconnectivity of the central brain regions holding a regulatory function of the autonomic and limbic system. Moreover, a recent PET/TC study demonstrated that heightened limbic activity precedes the development of TTS and that patients with the highest activity of the amygdala develop the syndrome earliest, supporting the hypothesis that a neurobiological substrate may predispose them to this clinical syndrome.

Of interest, since TTS has been identified in an increasing number of hospitalized patients, an important clinical heterogeneity emerged among those affected, and clinical characteristics such as physical triggers along with acute neurologic or psychiatric disease, high troponin levels, and low ejection fraction showed to identify a specific category of individuals with TTS at higher risk of mortality and in-hospital complications. Therefore, it is recently emerging that so far two different categories of TTS patients were described, with different clinical features and risk profiles: primary TTS, which mainly affects patients after an emotional stressor, in the absence of epicardial coronary disease, with minor troponin release, slightly reduced and rapidly reversed left ventricular (LV) dysfunction and benign prognosis; the second one of secondary TTS, occurring after a physical stressor, in the presence of epicardial coronary artery disease (CAD), with major troponin release, with more severe or persistent LV dysfunction and associated with worse prognosis. An interesting hypothesis, that remains to be tested, is that only primary TTS might result from reversible left ventricular dysfunction of neurogenic origin through activation of neurons originating in the limbic system which may cause reversible vasoconstriction of coronary microvasculature, while secondary TTS may be due to a direct catecholamine-induced myocardial damage provoked by a physical trigger in patients with concomitant CAD. However, the pathophysiological determinants of primary and secondary TTS respectively have never been investigated so far as well as a different brain-heart axis activation in these two categories of TTS patients has never been demonstrated.

Myocardial dysfunction following a physical stressor has been also described in sepsis-induced cardiomyopathy, a well-known systemic complication of the cytokine storm following the host immune response to infection, which can significantly affect the prognosis of these patients. Both left ventricular systolic dysfunction (LVSD) and LV diastolic dysfunction (LVDD) have been described in the first period of severe septic shock as in secondary TTS, but except for the reversible nature of the myocardial dysfunction, clinical and echocardiographic characteristics (e.g. typical left ventricular kinetic abnormalities, electrocardiographic features, and possible detrimental effects of vasopressors use) seemed to distinguish secondary TTS from sepsis-induced cardiomyopathy, thus suggesting a different host systemic response to the same "stressors" and different pathophysiological mechanisms underlying these clinical conditions.

Biochemical profiles of primary vs. secondary TTS patients are still largely unidentified, and whether a different profile exists associated with these two categories of patients remains unknown. The known mechanisms associated with the development of TTS include elevated levels of circulating plasma catecholamines and their metabolites. TTS has been reported to be characterized by a myocardial macrophage inflammatory infiltrate and an increase in systemic proinflammatory cytokines. Indeed, recent studies reported that patients with acute TTS had elevated levels of the pro-inflammatory cytokines IL-6, IL-8 and CXCL1 in the blood, however, to the best of our knowledge no study before ever investigated the inflammatory burden on primary and secondary TTS.

A pro-inflammatory response is also known as a key pathogenetic mechanism of sepsis-induced cardiomyopathy. Indeed, pro-inflammatory cytokines, such as tumor necrosis factor-alpha (TNF-α), interleukin-1-beta (IL-1β) and chemokines activated by pathogen-associated molecular patterns (PAMPs) have been implicated in the pathogenesis of the myocardial dysfunction following sepsis, as well as endothelial dysfunction and impaired endothelium-derived NO release which can alter the physiological regulation of blood flow distribution. Of note, in sepsis-induced cardiomyopathy, the altered immune response to pathogens leads to a down-regulation of β-adrenergic receptors, and to the attenuation of the adrenergic response at the cardiomyocyte level, as the opposite of what has been demonstrated in TTS. However, if different biological responses to the same stressors may underly the different clinical features of secondary TTS, sepsis-induced cardiomyopathy, and patients with sepsis/septic shock without myocardial dysfunction have never been investigated so far.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Parallel
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • For patients with TTS:
  • Informed consent signed by the patient or parent/guardian/legal representative.
  • TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as: (i) transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution; (ii) absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality; (iii) new electrocardiographic abnormalities or elevation in cardiac troponin values; (iv) absence of pheochromocytoma or myocarditis. N.B. - All TTS diagnosis made according to Mayo Clinic Diagnostic Criteria will be a posterior compared to fulfil the new InterTAK Diagnostic Criteria (19). Myocarditis will be suspected based on clinical presentation (e.g. previous flu-like symptoms, increased inflammatory biomarkers) and confirmed by cardiac magnetic resonance.N.B. - Of note, primary TTS mainly concerns post-menopausal women with symptoms resulting from myocardial damage, emotional trigger, and evidence of normal coronary arteries at coronary angiography, whilst secondary TTS equally affects men and women, with physical triggers and in the presence of possible coronary artery disease at coronary angiography.
  • For patients with sepsis:
  • Informed consent signed by the patient or parent/guardian/legal representative.
  • Diagnosis of sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more.
  • Septic a shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mmHg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia.
  • Sepsis-induced cardiomyopathy, defined as left ventricular systolic dysfunction (LVSD) and/or LV diastolic dysfunction (LVDD) following sepsis in patients without known structural or functional cardiac disease.

排除标准

  • Alternate diagnosis for the clinical presentation.
  • Contraindication to PET for patients with TTS (pregnancy, breast-feeding or patients considering becoming pregnant during the study period);
  • Patients with comorbidities having an expected survival <1-year.

研究组 & 干预措施

Septic patients

Experimental

Patients with diagnosis of sepsis and septic shock with or without concurrent LVSD or/and LVDD.

Diagnosis of sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, which can be represented by an increase in the Sequential [Sepsis-related] Organ Failure Assessment (SOFA) score of 2 points or more.

Septic shock, defined as vasopressor requirement to maintain a mean arterial pressure of 65 mm Hg or greater and serum lactate level greater than 2 mmol/L (>18 mg/dL) in the absence of hypovolemia.

Sepsis-induced cardiomyopathy, defined as left ventricular systolic dysfunction (LVSD) and/or LV diastolic dysfunction (LVDD) following sepsis in patients without known structural or functional cardiac disease.

干预措施: Blood samples collection (Diagnostic Test)

Takotsubo Syndrome

Experimental

Patients diagnosed with either primary or secondary Takotsubo Syndrome.

TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as:

  • Transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution;
  • Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality;
  • New electrocardiographic abnormalities or elevation in cardiac troponin values;
  • Absence of pheochromocytoma or myocarditis.

干预措施: Positron Emission Tomography (PET) analysis (Diagnostic Test)

Takotsubo Syndrome

Experimental

Patients diagnosed with either primary or secondary Takotsubo Syndrome.

TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as:

  • Transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution;
  • Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality;
  • New electrocardiographic abnormalities or elevation in cardiac troponin values;
  • Absence of pheochromocytoma or myocarditis.

干预措施: Blood samples collection (Diagnostic Test)

Takotsubo Syndrome

Experimental

Patients diagnosed with either primary or secondary Takotsubo Syndrome.

TTS diagnosed based on modified Mayo Clinic Diagnostic Criteria as:

  • Transient wall motion abnormality in the left ventricle beyond a single epicardial coronary artery distribution;
  • Absence of obstructive coronary artery disease or angiographic evidence of acute plaque rupture, which can explain the wall motion abnormality;
  • New electrocardiographic abnormalities or elevation in cardiac troponin values;
  • Absence of pheochromocytoma or myocarditis.

干预措施: Clinical follow up visit (Other)

结局指标

主要结局

Association between brain activation and clinical profile and outcome in Takotsubo Syndrome

时间窗: 3 months

To establish through an 18F-FDG-PET/CT analysis of brain structures involved in acute stress response if a different brain activation subtends to primary or secondary TTS. Brain activation will be evaluated through the tracer (18F-FDG) accumulation in the brain measured as standardized uptake value (SUV) and compared between the two subgroups.

次要结局

  • Association between IL-6 and Takotsubo clinical profile(Up to 3 months)
  • Association between hair cortisol levels and Takotsubo clinical profile(Up to 30 days)
  • Association between IL-18 and Takotsubo clinical profile(Up to 3 months)
  • Investigate IL-18 in sepsis/septic shock without cardiac dysfunction vs. sepsis-induced cardiomyopathy(Up to 3 months)
  • Investigate IL-1 beta in sepsis-induced cardiomyopathy vs secondary TTS(Up to 3 months)
  • Association between IL-1beta and Takotsubo clinical profile(Up to 3 months)
  • Investigate IL-1 beta in sepsis/septic shock without cardiac dysfunction vs. sepsis-induced cardiomyopathy(Up to 3 months)
  • Investigate IL-10 in sepsis/septic shock without cardiac dysfunction vs. sepsis-induced cardiomyopathy(Up to 3 months)
  • Investigate IL-6 in sepsis/septic shock without cardiac dysfunction vs. secondary TTS(Up to 3 months)
  • Investigate IL-10 in sepsis/septic shock without cardiac dysfunction vs. secondary TTS(Up to 3 months)
  • Investigate IL-6 in sepsis-induced cardiomyopathy vs secondary TTS(Up to 3 months)
  • Investigate IL-10 in sepsis-induced cardiomyopathy vs secondary TTS(Up to 3 months)
  • Investigate IL-18 in sepsis-induced cardiomyopathy vs secondary TTS(Up to 3 months)
  • Association between IL-10 and Takotsubo clinical profile(Up to 3 months)
  • Investigate IL-6 in sepsis/septic shock without cardiac dysfunction vs. sepsis-induced cardiomyopathy(Up to 3 months)
  • Investigate IL-1 beta in sepsis/septic shock without cardiac dysfunction vs. secondary TTS(Up to 3 months)
  • Investigate IL-18 in sepsis/septic shock without cardiac dysfunction vs. secondary TTS(Up to 3 months)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

MONTONE ROCCO ANTONIO

IRCCS Researcher

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

研究点 (2)

Loading locations...

相似试验